再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ZLAB 再鼎医药

休市中 04-17 16:00:00 EDT

28.84

-0.09

-0.33%

盘后28.84

+0.000.00%

19:49 EDT

最高29.22	最低28.34	成交量77.85万
今开28.93	昨收28.94	日振幅3.04%
总市值31.62亿	流通市值28.89亿	总股本1.10亿
成交额2,241万	换手率0.78%	流通股本1.00亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ZLAB","market":"US","secType":"STK","nameCN":"再鼎医药","latestPrice":28.84,"timestamp":1744920000000,"preClose":28.935,"halted":0,"volume":778494,"hourTrading":{"tag":"盘后","latestPrice":28.84,"preClose":28.84,"latestTime":"19:49 EDT","volume":20926,"amount":603509.63,"timestamp":1744933775006},"delay":0,"floatShares":100179140,"shares":109637154,"eps":-2.59837,"marketStatus":"休市中","change":-0.095,"latestTime":"04-17 16:00:00 EDT","open":28.93,"high":29.22,"low":28.34,"amount":22413281.330616,"amplitude":0.030413,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.59837,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":1,"adrRate":10,"listingDate":1505880000000,"exchange":"NASDAQ","adjPreClose":28.935,"preHourTrading":{"tag":"盘前","latestPrice":29,"preClose":28.935,"latestTime":"09:29 EDT","volume":42022,"amount":1237666.82226,"timestamp":1744896555041},"postHourTrading":{"tag":"盘后","latestPrice":28.84,"preClose":28.84,"latestTime":"19:49 EDT","volume":20926,"amount":603509.63,"timestamp":1744933775006},"volumeRatio":0.32627271226809257,"impliedVol":0.8785,"impliedVolPercentile":0.8406},"requestUrl":"/m/hq/s/ZLAB","defaultTab":"news","newsList":[{"id":"2528658081","title":"再鼎医药4月17日成交额为2239.40万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2528658081","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2528658081?lang=zh_cn&edition=full","pubTime":"2025-04-18 11:23","pubTimestamp":1744946594,"startTime":"0","endTime":"0","summary":"美东时间2025年4月17日，再鼎医药成交额为2239.40万美元，成交额较昨日减少40.04%，当日成交量为77.85万股。再鼎医药于2025年4月17日跌0.33%，报28.84美元，该股过去5个交易日涨18.59%，年初至今涨10.12%，过去60日涨8.3%。公司的专利候选药物产品管线包括 ZL-1218  实体瘤、ZL-1310  ES-SCLC 其他 NECs、ZL-6301  实体瘤、ZL6201  实体瘤。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250418112315a45d5d1e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250418112315a45d5d1e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","BK4531","BK4588","BK4585","BK4548","ZLAB","BK4139","LU2488822045.USD"],"gpt_icon":1},{"id":"2528781917","title":"中金：维持再鼎医药(09688)跑赢行业评级 目标价34.41港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2528781917","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2528781917?lang=zh_cn&edition=full","pubTime":"2025-04-17 09:15","pubTimestamp":1744852527,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，维持再鼎医药2025年和2026年盈利预测不变。该行维持跑赢行业评级，基于DCF模型，该行维持H/US股目标价34.41港元/44.24美元不变。4月11日，公司合作伙伴argenx宣布艾加莫德预充针皮下注射剂型获美国FDA批准上市。目前在国内，艾加莫德已有静脉输注和皮下注射2种给药方式，公司将于2025年在国内递交艾加莫德预充式皮下注射剂型的上市申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1279879.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09688","ZLAB"],"gpt_icon":1},{"id":"2527395722","title":"再鼎医药4月15日成交额为5139.17万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527395722","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2527395722?lang=zh_cn&edition=full","pubTime":"2025-04-16 11:11","pubTimestamp":1744773114,"startTime":"0","endTime":"0","summary":"美东时间2025年4月15日，再鼎医药成交额为5139.17万美元，成交额较昨日减少26.43%，当日成交量为168.78万股。再鼎医药于2025年4月15日跌3.62%，报30.38美元，该股过去5个交易日涨12.23%，年初至今涨16.0%，过去60日涨16.62%。公司的专利候选药物产品管线包括 ZL-1218  实体瘤、ZL-1310  ES-SCLC 其他 NECs、ZL-6301  实体瘤、ZL6201  实体瘤。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416111202a6bc0386&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416111202a6bc0386&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4548","BK4139","BK4526","LU2488822045.USD","BK4585","BK4531","BK4588","ZLAB"],"gpt_icon":1},{"id":"2527743865","title":"再鼎医药4月14日成交额为6984.99万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527743865","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2527743865?lang=zh_cn&edition=full","pubTime":"2025-04-15 11:03","pubTimestamp":1744686237,"startTime":"0","endTime":"0","summary":"美东时间2025年4月14日，再鼎医药成交额为6984.99万美元，成交额较昨日减少20.44%，当日成交量为218.27万股。再鼎医药于2025年4月14日涨6.7%，报31.52美元，该股过去5个交易日涨9.41%，年初至今涨20.35%，过去60日涨24.19%。公司的专利候选药物产品管线包括 ZL-1218  实体瘤、ZL-1310  ES-SCLC 其他 NECs、ZL-6301  实体瘤、ZL6201  实体瘤。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415110404a45931ce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415110404a45931ce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4526","ZLAB","BK4531","BK4139","BK4548","LU2488822045.USD","BK4588"],"gpt_icon":1},{"id":"2527147190","title":"再鼎医药上涨4.98%，报31.01美元/股，总市值34.15亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527147190","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2527147190?lang=zh_cn&edition=full","pubTime":"2025-04-15 00:00","pubTimestamp":1744646405,"startTime":"0","endTime":"0","summary":"4月15日，再鼎医药盘中上涨4.98%，截至00:00，报31.01美元/股，成交4502.02万美元，总市值34.15亿美元。财务数据显示，截至2024年12月31日，再鼎医药收入总额3.99亿美元，同比增长49.59%；归母净利润-2.57亿美元，同比增长23.17%。再鼎医药的长期目标是成为全球领先的生物制药公司,以中国为基,为全球患者提供创新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041500113997379d57&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041500113997379d57&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4531","BK4139","BK4548","BK4526","BK4585","LU2488822045.USD","BK4588","ZLAB"],"gpt_icon":0},{"id":"2527768191","title":"美股异动 | 再鼎医药(ZLAB.US)涨逾8% FDA批准艾加莫德预充式皮下注射剂型","url":"https://stock-news.laohu8.com/highlight/detail?id=2527768191","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2527768191?lang=zh_cn&edition=full","pubTime":"2025-04-14 22:59","pubTimestamp":1744642769,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周一，再鼎医药(ZLAB.US)盘中一度涨超13%，截至发稿，涨逾8%，报32.09美元。消息面上，4月11日，再鼎医药合作伙伴argenx公司宣布，美国食品药品监督管理局(FDA)已正式批准了艾加莫德预充式皮下注射剂型，用于治疗乙酰胆碱受体(AChR)抗体阳性的全身型重症肌无力(gMG)成人患者和慢性炎性脱髓鞘性多发性神经根神经病(CIDP)成人患者。再鼎医药表示，将于2025年在国内递交艾加莫德预充式皮下注射剂型的上市申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1278555.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"美股异动 | 再鼎医药(ZLAB.US)涨逾8% FDA批准艾加莫德预充式皮下注射剂型","news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","09688","BK4548","LU2488822045.USD","BK1161","ZLAB","BK4531","BK4585","BK4588","BK4526","BK1588","BK4139"],"gpt_icon":0},{"id":"2527916487","title":"再鼎医药盘中异动 早盘快速拉升6.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2527916487","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2527916487?lang=zh_cn&edition=full","pubTime":"2025-04-14 21:31","pubTimestamp":1744637498,"startTime":"0","endTime":"0","summary":"北京时间2025年04月14日21时31分，再鼎医药股票出现异动，股价大幅上涨6.57%。截至发稿，该股报31.48美元/股，成交量55.9304万股，换手率0.51%，振幅0.64%。机构评级方面，在所有17家参与评级的机构中，88%的券商给予买入建议，12%的券商给予持有建议，无券商给予卖出建议。再鼎医药股票所在的生物技术行业中，整体涨幅为0.67%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250414213138a4588e95&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250414213138a4588e95&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ZLAB","BK4531","BK4585","BK4139","LU2488822045.USD","BK4588","BK4548","BK4526"],"gpt_icon":0},{"id":"2527188984","title":"再鼎医药盘前续涨超6% 将于今年递交艾加莫德预充式皮下注射剂型上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2527188984","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2527188984?lang=zh_cn&edition=full","pubTime":"2025-04-14 16:22","pubTimestamp":1744618954,"startTime":"0","endTime":"0","summary":"再鼎医药(ZLAB.US)盘前续涨超6%，报31.32美元。该股上周五大幅收涨超21.4%。消息面上，4月11日，再鼎医药合作伙伴argenx公司宣布，美国食品药品监督管理局(FDA)已正式批准了艾加莫德预充式皮下注射剂型，用于治疗乙酰胆碱受体(AChR)抗体阳性的全身型重症肌无力(gMG)成人患者和慢性炎性脱髓鞘性多发性神经根神经病(CIDP)成人患者。再鼎医药表示，将于2025年在国内递交艾加莫德预充式皮下注射剂型的上市申请。\n\n\r\n            责任编辑：小讯","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2025/04/14162249519024.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK4588","BK4531","ZLAB","09688","BK4548","LU2488822045.USD","BK1588","BK4585","BK4139","BK1574","BK1161","BK4526"],"gpt_icon":0},{"id":"2527921945","title":"【券商聚焦】德邦证券：再鼎医药艾加莫德优势明显，维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2527921945","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2527921945?lang=zh_cn&edition=full","pubTime":"2025-04-14 11:31","pubTimestamp":1744601489,"startTime":"0","endTime":"0","summary":"艾加莫德作为全球首款FcRn拮抗剂，其快速起效和长期有效性、安全性优异的特点在临床试验中得到了充分验证。尽管存在临床研发失败、竞争格局恶化和行业政策风险，但艾加莫德的优势明显，有望成为新一代自免大单品，因此维持“买入”评级。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1957142","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZLAB","09688","161027"],"gpt_icon":0},{"id":"2527949291","title":"港股异动 | 医药股涨幅居前 再鼎医药(09688)涨近15% 和铂医药-B(02142)涨超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2527949291","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2527949291?lang=zh_cn&edition=full","pubTime":"2025-04-14 09:57","pubTimestamp":1744595830,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，医药股早盘涨幅居前，截至发稿，再鼎医药涨14.86%，报25.5港元；和铂医药-B涨10.07%，报7.87港元；荣昌生物涨8.22%，报30.95港元；君实生物涨8.1%，报15.22港元；来凯医药-B涨7.71%，报11.46港元。此外，财报层面：头部港股创新药公司受益于License-out放量，营收和利润稳步增长。该行表示，年初以来在DeepSeek的激励下，港股市场交投情形改善显著，相比之下，港股医药板块的关注度并不算高，对医药的基本面修复，市场定价或尚不充分。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1277939.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02105","BK1161","159938","LU2328871848.SGD","BK1588","BK4531","09939","09995","BK1515","LU1969619763.USD","ZLAB","09688","BK4548","BK4588","BK1583","BK1574","LU2488822045.USD","01877","BK4585","BK4526","02142","BK4139"],"gpt_icon":0},{"id":"2527945141","title":"港股生物医药板块盘初走强，再鼎医药涨超12%，君实生物涨超5%，百济神州、药明康德等跟涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2527945141","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2527945141?lang=zh_cn&edition=full","pubTime":"2025-04-14 09:44","pubTimestamp":1744595082,"startTime":"0","endTime":"0","summary":"港股生物医药板块盘初走强，再鼎医药涨超12%，君实生物涨超5%，百济神州、药明康德等跟涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/14094449514121.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["688180","BK1576","BK1500","HSTECH","LU2125910500.SGD","BK4531","399441","BK1588","06160","LU1997245094.SGD","LU2328871848.SGD","LU1969619763.USD","BK4526","BK0216","BK4548","BK4614","BK4139","BK1141","BK1515","09688","BK1574","LU0456842615.SGD","BK4585","161726","LU0052750758.USD","LU2045819591.USD","LU0708995583.HKD","LU1046422090.SGD","BK4588","LU2488822045.USD","603259","YANG","688235","ZLAB","ONC","BK1583","BK0239","01877","BK1161","LU2242644610.SGD","LU0320764599.SGD","LU0307460666.USD","LU1997245177.USD","02359","LU0588546209.SGD"],"gpt_icon":0},{"id":"2527945619","title":"港股生物医药板块盘初走强，再鼎医药(09688.HK)涨超12%，君实生物(01877.HK)涨超5%，百济神州(061","url":"https://stock-news.laohu8.com/highlight/detail?id=2527945619","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2527945619?lang=zh_cn&edition=full","pubTime":"2025-04-14 09:43","pubTimestamp":1744595016,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["399441","BK1576","06160","BK4585","LU0052750758.USD","688180","BK4531","BK1161","BK4548","BK4139","HSCEI","ONC","LU2045819591.USD","BK1500","BK1141","BK1583","688235","01877","BK1515","LU2242644610.SGD","HSTECH","BK0216","02359","LU2125910500.SGD","BK1574","LU0307460666.USD","BK1588","LU2488822045.USD","LU0320764599.SGD","BK4614","LU0708995583.HKD","ZLAB","BK0239","07226","LU1969619763.USD","09688","BK4526","LU0456842615.SGD","LU1997245094.SGD","LU2328871848.SGD","603259","161726","LU1997245177.USD","YANG","LU0588546209.SGD","LU1046422090.SGD","BK4588"],"gpt_icon":0},{"id":"2527945435","title":"【港股医药股多数走强 再鼎医药涨超13%】截至发稿，再鼎医药(09688.HK)涨13.51%、来凯医药-B(02105.HK)涨10.34%、基石药业-B(02616.HK)涨6.28%、腾盛博药-B(02137.HK)涨6.17%、药明合联(02268.HK)涨5.94%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2527945435","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2527945435?lang=zh_cn&edition=full","pubTime":"2025-04-14 09:42","pubTimestamp":1744594975,"startTime":"0","endTime":"0","summary":"截至发稿，再鼎医药(09688.HK)涨13.51%、来凯医药-B(02105.HK)涨10.34%、基石药业-B(02616.HK)涨6.28%、腾盛博药-B(02137.HK)涨6.17%、药明合联(02268.HK)涨5.94%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/14094249513998.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","BK4531","BK4526","LU2488822045.USD","BK4139","BK1588","02137","02616","BK4585","SG9999014674.SGD","BK4588","BK1574","BK4548","BK1161","02268","09688","159718","02105","ZLAB","BK1587"],"gpt_icon":0},{"id":"1193399009","title":"港股生物医药股大幅上涨，永泰生物-B涨超15%","url":"https://stock-news.laohu8.com/highlight/detail?id=1193399009","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193399009?lang=zh_cn&edition=full","pubTime":"2025-04-14 09:40","pubTimestamp":1744594831,"startTime":"0","endTime":"0","summary":"4月14日，港股生物医药股大幅上涨，$永泰生物-B(06978)$涨超15%，$再鼎医药(09688)$涨超13%，$荣昌生物(09995)$、$和铂医药-B(02142)$、$腾盛博药-B(02137)$涨超6%.","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1583","BK4139","LU2328871848.SGD","BK4588","ZLAB","BK4614","02142","BK1161","BK4585","07226","HSCEI","09995","BK4531","HSTECH","YANG","06978","02137","LU2488822045.USD","09688"],"gpt_icon":0},{"id":"2518220774","title":"再鼎医药盘中异动 早盘股价大跌5.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518220774","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518220774?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:01","pubTimestamp":1741615262,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时01分，再鼎医药股票出现波动，股价急速跳水5.35%。截至发稿，该股报34.47美元/股，成交量11.2824万股，换手率0.10%，振幅4.68%。再鼎医药股票所在的生物技术行业中，整体涨幅为0.12%。其相关个股中，Checkpoint Therapeutics, Inc.、Trevi Therapeutics, Inc.、Mineralys Therapeutics, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃，换手率分别为3092.10%、664.70%、298.02%，振幅较大的相关个股有Dogwood Therapeutics, Inc.、Scisparc Ltd.、Impact Biomedical, Inc.，振幅分别为41.36%、40.24%、28.59%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310220102a26a3005&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310220102a26a3005&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","ZLAB","BK4531","BK4526","BK4139","BK4585","BK4548"],"gpt_icon":0},{"id":"2517035469","title":"再鼎医药(ZLAB.US)获Scotiabank首次覆盖，给予跑赢大盘评级, 目标价55.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517035469","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517035469?lang=zh_cn&edition=full","pubTime":"2025-03-08 06:13","pubTimestamp":1741385596,"startTime":"0","endTime":"0","summary":"再鼎医药(ZLAB.US)获Scotiabank首次覆盖，给予跑赢大盘评级, 目标价55.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/08061348605305.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["09688","ZLAB"],"gpt_icon":0},{"id":"2517431171","title":"再鼎医药上涨5.31%，报37.27美元/股，总市值40.86亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517431171","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517431171?lang=zh_cn&edition=full","pubTime":"2025-03-07 22:55","pubTimestamp":1741359317,"startTime":"0","endTime":"0","summary":"3月7日，再鼎医药盘中上涨5.31%，截至22:55，报37.27美元/股，成交551.06万美元，总市值40.86亿美元。财务数据显示，截至2024年12月31日，再鼎医药收入总额3.99亿美元，同比增长49.59%；归母净利润-2.57亿美元，同比增长23.17%。大事提醒：3月3日，再鼎医药获美国银行重申评级Neutral，目标价上调至36.1美元。再鼎医药的长期目标是成为全球领先的生物制药公司,以中国为基,为全球患者提供创新疗法。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/07225548603508.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","BK1161","BK4588","BK4139","BK4531","BK4526","09688","BK1588","BK4548","BK4585","LU2488822045.USD","ZLAB"],"gpt_icon":0},{"id":"2517620291","title":"再鼎医药2024财年实现净利润-2.57亿美元，同比增加23.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517620291","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517620291?lang=zh_cn&edition=full","pubTime":"2025-03-07 00:00","pubTimestamp":1741276852,"startTime":"0","endTime":"0","summary":"3月7日，再鼎医药公布财报，公告显示公司2024财年净利润为-2.57亿美元，同比增加23.28%；其中营业收入为3.99亿美元，同比增加49.44%，每股基本收益为-2.60美元。从资产负债表来看，再鼎医药总负债3.45亿美元，其中短期债务1.40亿美元，资产负债比为3.44，流动比率为3.52。机构评级：截至2025年3月7日，当前有11家机构对再鼎医药目标价做出预测，其中目标均价为51.64美元，其中最低目标价为36.03美元，最高目标价为74.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000103abeb8cee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000103abeb8cee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ZLAB"],"gpt_icon":0},{"id":"2517838134","title":"再鼎医药(09688)根据2024年股权激励计划授出可认购合共4700股美国存托股份的购股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2517838134","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517838134?lang=zh_cn&edition=full","pubTime":"2025-03-06 17:30","pubTimestamp":1741253414,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布公告，于2025年3月3日(美国东部时间)，公司根据2024年股权激励计划向3名承授人授出可认购合共4700股美国存托股份的购股权并向9名承授人涉及合共1.01万股美国存托股份的受限制股份单位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258598.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","ZLAB","BK4531","BK4548","BK4526","BK4585","BK1161","LU2488822045.USD","09688","BK4588","BK4139","BK1574"],"gpt_icon":0},{"id":"2517135516","title":"财报发布后获多家投行一致看多 商业化加速兑现驱动再鼎医药价值重估","url":"https://stock-news.laohu8.com/highlight/detail?id=2517135516","media":"格隆汇","labels":["viewpoints"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517135516?lang=zh_cn&edition=full","pubTime":"2025-03-06 16:46","pubTimestamp":1741250793,"startTime":"0","endTime":"0","summary":"在业绩披露窗口期，创新药企的成长韧性正在接受市场检验。财报发布后也引起了国内外多家投行的关注和分析。多家机构普遍认为，以再鼎医药为代表的中国创新药企或已进入商业化能力验证与管线价值释放的双击周期。针对其后续的市场表现，多家投行持续表达了积极乐观的预期，并上调目标价。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306164648963bee52&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306164648963bee52&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"财报发布后获多家投行一致看多 商业化加速兑现驱动再鼎医药价值重估","news_tag":"viewpoints","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09688","ZLAB"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zailaboratory.com","stockEarnings":[{"period":"1week","weight":0.1859},{"period":"1month","weight":-0.2395},{"period":"3month","weight":0.1071},{"period":"6month","weight":0.0491},{"period":"1year","weight":1.102},{"period":"ytd","weight":0.1012}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"再鼎医药有限公司是一家主要从事生物制药的控股公司。该公司致力于通过产品的发现、开发和商业化解决肿瘤、自身免疫疾病、感染性疾病和中枢神经系统疾病领域未被满足的医疗需求。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物。其中包括“则乐”、“OPTUNE”、“擎乐”、“纽再乐”及“卫伟迦”等。","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.10392},{"month":2,"riseRate":0.5,"avgChangeRate":0.014818},{"month":3,"riseRate":0.25,"avgChangeRate":-0.083122},{"month":4,"riseRate":0.375,"avgChangeRate":-0.001731},{"month":5,"riseRate":0.571429,"avgChangeRate":0.03934},{"month":6,"riseRate":0.428571,"avgChangeRate":0.063316},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.00593},{"month":8,"riseRate":0.714286,"avgChangeRate":0.018507},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.066935},{"month":10,"riseRate":0.5,"avgChangeRate":-0.024776},{"month":11,"riseRate":0.625,"avgChangeRate":0.141461},{"month":12,"riseRate":0.5,"avgChangeRate":-0.016217}],"exchange":"NASDAQ","name":"再鼎医药","nameEN":"Zai Lab Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再鼎医药(ZLAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再鼎医药,ZLAB,再鼎医药股票,再鼎医药股票老虎,再鼎医药股票老虎国际,再鼎医药行情,再鼎医药股票行情,再鼎医药股价,再鼎医药股市,再鼎医药股票价格,再鼎医药股票交易,再鼎医药股票购买,再鼎医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再鼎医药(ZLAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}